Intellia Therapeutics specializes in genome editing technology to develop gene therapy treatments for a variety of conditions. Its programs include in vivo treatments for liver disorders and ex vivo treatments for cell therapy for leukemia, oncological, and autoimmune disorders. The company has also partnered with several institutions to develop potential products for the treatment of hemophilia A and B and sickle cell disease, as well as for ocular diseases.